# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-30T15:45:53.912498

---

**Idea Fidelity**

The paper adheres closely to the manifest. It uses the ARCOS universe, exploits the late-2007 DEA suspensions of Cardinal Health distribution center licenses, and relies on pre-enforcement county-level Cardinal market share as the exposure intensity. The event-study DiD with county and time fixed effects, the decomposition into distributor-specific flows, and the focus on the “waterbed” question (total supply vs. reallocation) are all exactly as advertised. I found no major deviations from the originally proposed identification strategy, data source, or research question.

**Summary**

This paper exploits the 2007 DEA suspension of Cardinal Health distribution centers to test whether targeting one distributor meaningfully reduced aggregate opioid supply or merely rerouted flows among competing distributors. Using the ARCOS universe at the county-quarter level and pre-treatment Cardinal market share as continuous exposure, the author shows that while Cardinal shipments plunged in exposed counties, total county-level pills barely budged and competitors absorbed much of the volume—evidence of a supply-chain “waterbed effect.” The result implies that firm-level enforcement against a single distributor can displace rather than eliminate opioid availability in the presence of close substitutes.

**Essential Points**

1. **Parallel Trends and Pre-treatment Dynamics.** The event study suggests high-Cardinal counties were growing faster than low-Cardinal counties before 2008, which the author interprets as conservative. However, if pre-trends differ, the identifying assumption of the DiD is threatened. The analysis should more directly address whether the positive 2006 coefficient reflects a diverging trend or merely a level difference. A more flexible replacement (e.g., county-specific linear trends, matching on pre-trends, or synthetic control-style weighting) is needed to ensure the subsequent null effect on total pills is not driven by existing divergence that would have continued absent enforcement.

2. **Confounding State-Level Policy Changes.** The treatment (Cardinal share × post) could be capturing other coincident, state- or regional-level policies that differentially affected counties with higher Cardinal exposure (e.g., early prescription monitoring programs, Medicaid policy changes). While the author adds state×quarter fixed effects in one specification, the standard errors remain clustered at the state level and the primary estimates use only county and quarter FE. Strengthening the identification by, for example, conditioning on county-specific time trends, including state×year interactions throughout, or exploiting variation across the three affected distribution center states versus others would help rule out such confounders.

3. **Mechanism and Spillovers.** The waterbed interpretation rests on reallocation to competitors, but the analysis does not fully demonstrate how much of the displaced supply is absorbed within the same county versus through spillovers (e.g., increased shipments from other counties routed through the same pharmacies). The paper would benefit from evidence that increases in McKesson/Amerisource shipments occur within the ex-ante exposed counties (rather than through neighboring counties) and that the pharmacies affected actually increased orders with new distributors. Without this, the paper risks conflating supply-side resilience inside counties with broader geographic redistribution.

**Suggestions**

- **Address Pre-treatment Trends More Thoroughly.** The positive 2006 coefficient implies diverging trends, which might bias the main estimates. Consider presenting figures (in addition to or instead of the event-study table) that plot average log total pills for high- versus low-Cardinal counties over time, showing whether the pre-2008 slopes are parallel. Alternatively, estimate the main specification with county-specific linear trends or with leads of the treatment interacted with Cardinal share to formally test for pre-treatment dynamics beyond 2006. If trends differ, match counties on pre-treatment growth or use inverse propensity weighting to construct a better counterfactual.

- **Alternative Identification Checks.** Re-estimate the main specification with county fixed effects interacted with linear time trends, or include state×quarter fixed effects in all specifications (not just column (2)), to ensure the null total-supply effect isn’t picking up other contemporaneous shocks. You could also exploit the fact that the suspensions occurred in specific distribution centers: compare counties that previously relied on those centers versus those exposed to Cardinal through other facilities, thereby adding a spatial dimension to the exposure that is plausibly exogenous. Another variation is to instrument for post-treatment Cardinal shipments using the suspension dates directly where the instrument is the county’s pre-period reliance on the affected centers.

- **Direct Evidence on Reallocation.** The narrative around reallocation would be stronger if you show, for example, that the total increase across all non-Cardinal distributors roughly equals the Cardinal decline (perhaps aggregating across smaller distributors). Alternatively, plot the change in McKesson/Amerisource shipments by quintile of pre-treatment Cardinal share to show a dose-response. You could also restrict attention to pharmacies with high pre-treatment Cardinal dependence and track their distributor switches over time—do they add McKesson or Amerisource contracts after the suspension? Evidence from the pharmacy level would sharpen the story that the waterbed effect operates through supplier switching rather than demand change.

- **Explore Heterogeneous Effects.** The robustness appendix proxies for heterogeneity with SDEs, but you could provide more substantive heterogeneity analysis. For example, do rural versus urban counties differ in how much displacement occurs? Is the waterbed effect weaker in counties with fewer alternative distributors (e.g., low-density areas)? Such heterogeneity would speak directly to policy implications about where distributor enforcement might still have bite.

- **Clarify Standard Error Strategy.** The paper clusters standard errors at the state level, but the treatment varies continuously across counties. It would help to justify this choice vis-à-vis the number of clusters, especially since the event-study uses multiple interaction terms. You might also report wild bootstrap or two-way clustering as a robustness check, particularly if the state-level shocks align with enforcement timing.

- **Discuss Demand-Side Counterparts.** The paper argues that aggregate demand is unchanged, but opioid demand itself may respond to supply shocks (e.g., if pharmacies delay filling). A brief analysis of prescription-level outcomes (e.g., average days supply, average dose per prescription) or including pharmacy-level controls would help rule out demand-side adjustments being mistaken for supply displacement.

- **Policy Framing.** Given the null result on total supply, consider elaborating on the potency of alternative policies (quotas, distributor-level oversight) and whether similar waterbed effects might emerge if all large distributors face enforcement simultaneously. This would position your contribution more sharply for policy audiences and clarify when enforcement might still be effective.

- **Transparency around Data Construction.** The paper mentions aggregating 178 million ARCOS transactions, but readers would benefit from more detail on how county-level totals are constructed (e.g., handling of missing county identifiers, smoothing across quarters, treatment of pharmacies supplied by multiple distribution centers). A short paragraph or appendix table describing data cleaning steps and any imputation would strengthen confidence in the results.

In sum, the paper addresses an important policy question with rich data. With additional attention to parallel trends, alternative identification checks, and deeper mechanism analysis, the study would make a strong contribution to the enforcement and opioid supply literature.
